| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
CollPlant Biotechnologies Ltd.$0.36
0 (0%)
Market Cap
6.15 M
EPS
-0.93
P/E Ratio
-
Value Trade
27.92 K
-1.95 %
Week
4.25 %
1 Month
-31.21 %
3 Month
-79.2 %
6 Month
-97.15 %
5 Year
-97.69 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
9.00 K
52 Week Range
0.27 - 4.98
% held by Insiders
28.21 %
% held by Institutions
10.61 %
Enterprise Value
3.04 M
Total Shares
14.42 M
Short %
0.21 %
Float Shares
10.22 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for CollPlant Biotechnologies Ltd.
1Total events
0Upcoming
0Tier-1 (high impact)
2026 – 2026Coverage
Event history 1
Jul 1, 2026
▼Equity OfferingCorporate
Private placement of ordinary shares and warrants for $2.6 million gross proceeds
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Collink.3D™ | tissue engineering and regenerative medicine | — | 2025-10-20 | enhanced mechanical strength; elasticity; stability | CollPlant's rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion - Israel Institute of Technology Read More | |
Collink.3D™ | tissue engineering and regenerative medicine | — | 2025-10-20 | enhanced mechanical strength; elasticity; stability | CollPlant's rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion - Israel Institute of Technology Read More | |
Collink.3D™ | tissue engineering and regenerative medicine | — | 2025-10-20 | enhanced mechanical strength; elasticity; stability | CollPlant's rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion - Israel Institute of Technology Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CLGN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CLGN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CLGNCOLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.6 MILLION PRIVATE PLACEMENT
CollPlant Biotechnologies has announced a definitive agreement for a private placement, raising approximately $2.6 million through the sale of ordinary shares and warrants. The funds will be used for general corporate purposes, including R&D and potential strategic transactions. The placement is expected to close by July 1, 2026, pending customary conditions.
Read more →CLGNCOLLPLANT BIOTECHNOLOGIES REPORTS 2026
CollPlant Biotechnologies reported its financial results for Q1 2026, revealing a significant revenue decline and increased net losses compared to Q1 2025. The company is pursuing collaborations in medical aesthetics and has made progress in the development of next-generation dermal fillers. Additionally, it launched BioFlex, a rhCollagen-based kit for bioprinting. However, the financial outlook is strained, reflected in increased operational losses and cash usage.
Read more →CLGNCOLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CollPlant Biotechnologies has announced its financial results for the first quarter of 2026, highlighting its ongoing commitment to developing innovative products based on recombinant human collagen. The company continues to focus on applications in tissue regeneration and medical aesthetics. This update reflects CollPlant's strategic direction and financial health.
Read more →CLGN▼ -15.7%on this news
Letter to Shareholders Collaborations As noted, Allergan Industrie SAS, an AbbVie company, notified us that it was exercising its right to terminate the development agreement, previously entered into in February 2021 , u
CollPlant has announced the termination of its development agreement with AbbVie, signaling a potential shift in strategy. The company remains optimistic about future opportunities in the aesthetics market, particularly focusing on its rhCollagen technology for dermal and soft tissue fillers. Despite the workforce reduction as part of a cost-optimization plan, CollPlant is actively seeking new strategic partners and planning clinical trials for its innovative products. The company emphasizes its commitment to growth and is confident about extending its cash runway into 2026.
Read more →CLGN▼ -15.7%on this news
CollPlant Issues Letter to Shareholders
CollPlant announced the termination of its development agreement with AbbVie, viewing it as a new opportunity. The company is pursuing partnerships for aesthetic products and implementing cost-reduction measures, including a significant workforce reduction. CollPlant aims to advance its innovative technologies in dermal fillers and breast implants while extending its cash runway into late 2026.
Read more →CLGN▼ -12%on this news· ran to -29% by day 3
COLLPLANT BIOTECHNOLOGIES REPORTS 2025
CollPlant Biotechnologies reported its 2025 financial results, showcasing significant progress in its regenerative and aesthetic medicine technologies. The company achieved a development milestone that facilitated a $2 million payment from AbbVie, expanded its distribution network into North America, and advanced its proprietary product line. Noteworthy achievements included the successful results from clinical trials of regenerative breast implants, and the development of a humanized 3D bioprinted skin model by Mayo Clinic using CollPlant's rhCollagen technology. Additionally, the company secured new patents related to its dermal filler technology, enhancing its intellectual property portfolio.
Read more →CLGN▼ -12%on this news· ran to -29% by day 3
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CollPlant Biotechnologies reported its 2025 financial results, showcasing a significant revenue increase to $2.4 million, driven by a milestone payment from AbbVie. The company expanded its distribution into North America and strengthened its intellectual property with new patents. Despite a net loss of $11.5 million, CollPlant remains focused on innovation in regenerative medicine and 3D bioprinting.
Read more →CLGN▲ +17.1%on this newsshared move
CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement
CollPlant Biotechnologies received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, as its stock price has been below $1.00 for 30 consecutive days. The company has a 180-day compliance period to regain compliance, with the option for a second period if necessary. During this time, its shares will continue to trade on Nasdaq.
Read more →CLGNCollPlant Biotechnologies Launches Redesigned Corporate Website
CollPlant Biotechnologies has launched a redesigned corporate website aimed at improving transparency and accessibility for investors and partners. The new platform features comprehensive information on the company's proprietary rhCollagen technology, product pipeline, and strategic collaborations. According to CEO Yehiel Tal, the update reflects the company's commitment to advancing in the regenerative medicine and aesthetics sectors, with a focus on enhancing stakeholder engagement. The website will serve as a central resource for CollPlant's scientific programs and corporate updates.
Read more →CLGNCOLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTS
CollPlant Biotechnologies has announced that it will release its financial results for the full year of 2025 on March 26, 2026, prior to the opening of U.S. markets. As a leader in regenerative and aesthetic medicine, CollPlant focuses on developing products based on non-animal-derived collagen. The company has a notable partnership with Allergan for the global commercialization of dermal fillers. This financial announcement highlights the company's ongoing progress and contributions to the fields of tissue regeneration and aesthetics.
Read more →CLGNCollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler
CollPlant Biotechnologies has secured a patent allowance from the Korean Patent Office for its innovative photocurable dermal filler technology. This patent covers a polymerizable solution used for tissue augmentation, enhancing the company's intellectual property in the aesthetic market. CEO Yehiel Tal emphasized the strategic importance of this patent for expanding their rhCollagen platform in high-value markets. The technology aims to provide long-term contour stability and tissue integration.
Read more →CLGNCollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex
CollPlant has launched BioFlex, a ready-to-print rhCollagen-based kit for Digital Light Processing 3D bioprinting. This innovative solution is designed to facilitate the biofabrication of advanced tissue models and engineered organs, significantly reducing development time. BioFlex integrates biodegradable polymers and photoactive agents, enabling precise fabrication of complex structures. The product aims to empower researchers in biopharma and academia with high-performance bioprinting solutions.
Read more →CLGN▼ -11.9%on this news
CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments
CollPlant Biotechnologies announced a strategic focus on addressing facial volume loss in patients using GLP-1 weight-loss therapies. The company is advancing its photocurable dermal filler technology, which aims to restore facial structure and skin quality through a supportive regenerative matrix. With the rising adoption of GLP-1 treatments, CollPlant positions itself to meet the growing aesthetic needs for patients experiencing rapid weight loss. The technology is currently in preclinical development and aims to combine immediate structure restoration with long-term tissue improvement.
Read more →CLGN▼ -53.4%on this news
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING
CollPlant Biotechnologies has announced a registered direct offering of 1.6 million ordinary shares at $1.25 each, aiming to raise approximately $2 million. The proceeds will be utilized for general corporate purposes, including research and development. The offering is expected to close on February 6, 2026, pending customary conditions. H.C. Wainwright & Co. is the exclusive placement agent for this transaction.
Read more →CLGN▼ -53.4%on this newsshared move
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0
CollPlant Biotechnologies announced a definitive agreement for a registered direct offering of 1,600,000 ordinary shares at a price of $1.25 each, aiming to raise approximately $2.0 million. The funding will be utilized for general corporate purposes, including research and development activities. Concurrently, the company will issue unregistered series A and B warrants for the shares. The offering is expected to close on or about February 6, 2026, subject to customary closing conditions.
Read more →CLGNCOLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CollPlant Biotechnologies reported its third quarter financial results for 2025, showcasing significant revenue growth driven by its rhCollagen products. The company highlighted advancements in its technology, including a bioprinted skin model developed with Mayo Clinic. However, it announced a workforce reduction plan to prioritize key collaborations and product developments amid ongoing net losses.
Read more →CLGNCollPlant Biotechnologies Ltd. 4 Oppenheimer St, Weizmann Science Park Rehovot 7670104, Israel NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To be held on Wednesday
CollPlant Biotechnologies Ltd. has announced an annual and extraordinary general meeting scheduled for December 31, 2025, in Tel-Aviv, Israel. Key agenda items include the renewal of the compensation policy for directors and officers and the appointment of Mr. Yehiel Tal as interim Chairman of the Board. Shareholders will also have the opportunity to review the financial results for the fiscal year ending December 31, 2024. Proxy voting details and the rights of shareholders to propose additional agenda items are included in the announcement.
Read more →CLGNCOLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2025 THIRD QUARTER FINANCIAL RESULTS
CollPlant Biotechnologies, a company focused on regenerative and aesthetic medicine, will report its financial results for the third quarter of 2025 on November 26, 2025. The company specializes in developing products based on its non-animal-derived rhCollagen, employing proprietary plant-based genetic engineering technology. Notably, CollPlant has a global commercialization agreement with Allergan for dermal and soft tissue fillers, marking a significant collaboration in the aesthetics market.
Read more →CLGNCollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada
CollPlant Biotechnologies has announced the opening of a new logistics center in the U.S. to enhance the distribution of its rhCollagen and BioInk products. This facility will provide cGMP-compliant storage and distribution services, supporting the company's growth in North America. The center aims to improve efficiency and customer access to products.
Read more →CLGN▲ +7.3%on this news
CollPlant's rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion - Israel Institute of Technology
CollPlant Biotechnologies announced positive results from a study comparing its rhCollagen-based bioink, Collink.3D™, with Matrigel®. Conducted by the Technion, the study highlighted Collink.3D™'s superior mechanical properties and potential as an animal-free extracellular matrix. The findings suggest it could enhance tissue engineering and regenerative medicine applications.
Read more →CLGNFirst-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk
CollPlant Biotechnologies announced that Mayo Clinic researchers have developed a fully humanized 3D bioprinted skin model using CollPlant's rhCollagen. This innovative model serves as a non-animal alternative for preclinical research, with applications in drug development and disease modeling. The technology promises high-throughput production of personalized skin models, enhancing regenerative medicine efforts.
Read more →CLGN▼ -12.9%on this news
CollPlant Biotechnologies Announces Positive Results from non-clinical Studies of its Photocurable Regenerative Dermal and Soft Tissue Filler
CollPlant Biotechnologies has announced positive results from its non-clinical studies of a photocurable dermal filler, which integrates contouring precision and tissue regeneration. The company plans to advance this innovative product into clinical trials while optimizing its manufacturing process. This development marks a significant milestone in aesthetic medicine, aiming to redefine care standards.
Read more →CLGNCollPlant Expands the Distribution of its VergenixSTR Product in Europe
CollPlant Biotechnologies announced the expansion of its European distribution for VergenixSTR, a product designed to treat tendon injuries. The product utilizes rhCollagen technology and is intended for various tendon-related conditions. CEO Yehiel Tal highlighted the significant market potential and the expected first shipment by year-end.
Read more →CLGNCollPlant to Present at the 2025 International Conference on Biofabrication
CollPlant Biotechnologies will present at the International Conference on Biofabrication 2025 in Warsaw, Poland, from September 14-17. The company will showcase its rhCollagen technology and host an exhibition booth. The conference aims to discuss advancements in biofabrication and 3D printing applications in regenerative medicine.
Read more →CLGNCollPlant to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
CollPlant Biotechnologies will participate in the 27th Annual H.C. Wainwright Global Investment Conference on September 8-9, 2025. Senior management will be available for one-on-one meetings with investors. The company focuses on regenerative and aesthetic medicine, utilizing its proprietary rhCollagen technology.
Read more →CLGN▼ -20.2%on this newsshared move
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CollPlant Biotechnologies reported its second quarter financial results for 2025, highlighting advancements in its photocurable dermal filler program and regenerative breast implants. The company raised $3.6 million in a direct offering to support its initiatives. Despite a decrease in revenues and a net loss, the firm remains optimistic about its collaborations and product development.
Read more →CLGNCOLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR SECOND QUARTER FINANCIAL RESULTS
CollPlant Biotechnologies, a company specializing in regenerative and aesthetics medicine, has announced that it will release its second quarter financial results on August 20, 2025, prior to the U.S. markets opening. The company focuses on developing products using its proprietary rhCollagen technology. It has also entered into a partnership with Allergan for the commercialization of dermal and soft tissue fillers, indicating potential growth in its product offerings.
Read more →CLGN▲ +15.3%on this news· ran to +26% by day 3
CollPlant Appoints Collagen Biomaterials Expert as New Head of North America Commercial Operations
CollPlant Biotechnologies has appointed Bowman Bagley as Vice President of Commercial North America to enhance its growth strategy and market presence. With extensive experience in collagen biomaterials and a proven track record in sales and product development, Bagley is expected to play a crucial role in expanding CollPlant's rhCollagen-based products. This strategic appointment comes as the company seeks to establish itself further in the regenerative and aesthetic medicine sector, though it faces challenges related to funding and regulatory approvals.
Read more →CLGN▼ -10.8%on this news
COLLPLANT BROADENS ITS COLLABORATION WITH STEMCELL TECHNOLOGIES
CollPlant Biotechnologies announced an expanded collaboration with STEMCELL Technologies, allowing for broader use of its plant-derived rhCollagen in clinical and commercial contexts. The partnership aims to address the increasing demands in the life sciences market and promotes the ethical sourcing of materials. CollPlant's CEO emphasized the transition from research to commercial-scale applications as a significant milestone. However, the company faces financial uncertainties and challenges in advancing clinical trials, which could affect the realization of these opportunities.
Read more →CLGN▼ -13.4%on this news· ran to -32% by day 3shared move
COLLPLANT BIOTECHNOLOGIES ANNOUNCES EUROPEAN PATENT ALLOWANCE SECURED FOR ITS COLLAGEN-BASED FORMULATIONS USABLE AS SOFT TISSUE FILLERS AND IMPLANTS
CollPlant Biotechnologies has announced the allowance of a European patent for its innovative collagen-based formulations intended for soft tissue fillers and regenerative breast implants. This patent supports the company's strategy to enter lucrative markets, including a growing $6 billion soft-tissue filler sector and an estimated $3 billion breast implant sector. The technology emphasizes biocompatibility and aims to enhance tissue regeneration, offering potential improvements over existing solutions. However, the company faces challenges such as previous financial losses and the need for regulatory approvals as it moves forward in these competitive markets.
Read more →CLGN▼ -30%on this news· ran to -52% by day 3shared move
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $3.6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
CollPlant Biotechnologies has announced a registered direct offering of $3.6 million, pricing the shares at $3.00 each. This move aims to strengthen the company's financial position and bolster its operations, particularly in its partnership with AbbVie concerning dermal fillers. The offering is set to close on or about June 2, 2025, pending customary conditions. CollPlant plans to utilize the proceeds for general corporate purposes, which include research and development initiatives.
Read more →CLGN▲ +76.2%on this news· ran to +135% by day 1shared move
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE
CollPlant Biotechnologies announced its financial results for Q1 2025, highlighting a $2 million milestone payment from AbbVie, signaling progress in their collaborative dermal filler project. The company is advancing its innovative regenerative breast implant program, which has shown encouraging preclinical findings, suggesting a potential breakthrough in aesthetic and reconstructive medicine. Additionally, developments in their photocurable dermal filler are nearing clinical trials, with enhanced capabilities for facial aesthetics. These advancements position CollPlant favorably in its market sector.
Read more →CLGN▲ +5.5%on this news
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS
CollPlant Biotechnologies has announced the date for its first-quarter financial results, set to be reported on May 28, 2025, before U.S. markets open. The company specializes in regenerative and aesthetic medicine, utilizing its rhCollagen technology for tissue regeneration and medical aesthetics. CollPlant has established a notable partnership with Allergan for dermal fillers, positioning itself well in the marketplace. This announcement underscores CollPlant's commitment to transparency and innovation in the medical field.
Read more →CLGNCollPlant's Collink.3D® BioInks and Technologies Offer a Relevant and Timely Solution to FDA's Plan to Reduce Animal Testing in Preclinical Safety Studies CollPlant Biotechnologies (NASDAQ: CLGN), or CollPlant , a regenerative and aesthetics medicine company developing innovative technologies and...
CollPlant Biotechnologies announced that its rhCollagen-based Collink.3D BioInks offer a timely solution to the FDA's plan to reduce animal testing in preclinical safety studies. The FDA's initiative aims to develop more effective, human-relevant methodologies for drug development. CollPlant's BioInk products can be deployed in biofabrication systems, enhancing drug safety, reducing R&D costs, and promoting ethical research practices. CEO Yehiel Tal highlighted that their technology supports the FDA's New Approach Methodologies and anticipates playing a crucial role over the next five years.
Read more →CLGNCOLLPLANT BIOTECHNOLOGIES REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE
CollPlant Biotechnologies has reported its 2024 financial results and provided an update on its regenerative breast implant program, indicating significant progress. The company announced successful six-month data from clinical trials of its bioprinted breast implants and received a $2 million payment from AbbVie for development milestones. Additionally, CollPlant is expanding distribution for its Vergenix STR product in Europe and Asia. However, the company is also implementing a cost-cutting plan, reducing its workforce by 20% to maintain operations.
Read more →CLGNCOLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
CollPlant Biotechnologies has announced that it will release its financial results for the fourth quarter and full year of 2024 on March 26, 2025, prior to U.S. market opening. A conference call will be held at 10:00 a.m. EST to discuss these results and provide corporate updates. The company specializes in regenerative medicine and has partnered with Allergan for product development in medical aesthetics. Investors can participate in the call via specified dial-in numbers or by accessing a live webcast.
Read more →CLGN▼ -6.1%on this news
CollPlant Expands Distribution for its VergenixSTR Product in Europe and Asia
CollPlant Biotechnologies has announced the expansion of its distribution network for its VergenixSTR product across various territories in Europe and Asia. The product, which utilizes rhCollagen technology, is designed to treat tendon injuries and promotes healing through a gel matrix that releases growth factors. Recent distribution agreements have been signed with companies in the Netherlands, Turkey, and India, with an aim to start sales in 2025. The CEO emphasized the market potential and future expansion plans for the VergenixSTR product in new territories.
Read more →CLGNCollPlant Biotechnologies Provides a Corporate Update
CollPlant Biotechnologies has provided a corporate update highlighting the granting of a new U.S. patent for its photocurable dermal filler. The company continues its collaboration with AbbVie, receiving a $2 million contingent payment related to their ongoing clinical trials. Additionally, CollPlant has announced cost reductions, including a workforce cut of about 20%, to extend its cash runway. These actions are intended to allow the company to sustain its research and development efforts at least until mid-2026.
Read more →CLGNCOLLPLANT BIOTECHNOLOGIES REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CollPlant Biotechnologies reported its third quarter financial results for 2024, highlighting promising preclinical outcomes for its 3D-printed regenerative breast implants. The company noted a significant market potential in a $3 billion sector, as it moves closer to human studies with its innovative implants. However, CollPlant also faced financial challenges, reporting a significant drop in revenues and a net loss of $4.3 million. The company is focusing on collaboration opportunities and adjusting its operational plans to maintain financial stability.
Read more →CLGN▲ +10.8%on this news
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
CollPlant Biotechnologies has announced the date for its third quarter 2024 financial results, to be reported on November 27, 2024, prior to market opening. Following the results announcement, the company will host a conference call at 10:00 a.m. EST to discuss the financial performance and provide corporate updates. Investors can participate via dial-in numbers or access a live webcast for the details, ensuring transparency and engagement with stakeholders.
Read more →CLGNCollPlant Biotechnologies Ltd. 4 Oppenheimer St, Weizmann Science Park Rehovot 7670104, Israel NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To be held on Tuesday
CollPlant Biotechnologies Ltd. will hold its Annual and Extraordinary General Meeting of Shareholders on September 25, 2024, in Tel-Aviv, Israel. Shareholders registered by August 26, 2024, are entitled to vote on the proposals laid out by the Board of Directors, which unanimously recommends voting 'FOR' the agenda. The meeting will also include a review of the financial statements for the fiscal year ended December 31, 2023. Shareholders are encouraged to participate in person or through proxies.
Read more →CLGNCOLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CollPlant Biotechnologies reported its financial results for Q2 2024, showing a significant revenue decline while announcing the initiation of a pre-clinical trial for its 3D printed regenerative breast implants. The cash balance stood at $18.9 million, providing operational runway until late 2025. Despite advancements in their product development and launching their first ESG report, the company experienced net losses during the quarter, mirroring a broader trend of reduced revenues compared to the previous year.
Read more →CLGN▲ +5.5%on this newsshared move
CollPlant and Stratasys Announce Pre-clinical Study for Regenerative Commercial-Sized Breast Implants 3D Printed Breast implants consisting of 200cc in volume of CollPlant's rhCollagen- based bioinks produce
CollPlant and Stratasys have announced the initiation of a pre-clinical study on 3D printed regenerative breast implants, targeting a market estimated at $3 billion. The study will focus on the ability of these implants to grow natural breast tissue and fully biodegrade. This collaboration marks a significant advancement in regenerative medicine, aiming to provide safer alternatives to conventional silicone implants. Results from the study are anticipated in the first half of 2025, highlighting both companies' commitment to innovation in healthcare solutions.
Read more →CLGN▲ +5.5%on this newsshared move
CollPlant and Stratasys Announce Pre-clinical Study for Regenerative Commercial-Sized Breast Implants
CollPlant Biotechnologies and Stratasys Ltd. have announced the initiation of a pre-clinical study for 3D printed breast implants using CollPlant's rhCollagen-based bioinks. This study will assess the implants' ability to support natural breast tissue growth and biodegrade over time. The collaboration marks a significant advancement in regenerative medicine, aiming to provide a safer alternative to traditional silicone implants. Initial study results are expected in the first half of 2025, following positive outcomes from previous research.
Read more →CLGNCOLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 SECOND QUARTER FINANCIAL STATEMENTS AND CONFERENCE CALL INFORMATION
CollPlant Biotechnologies has announced the date for its second quarter financial statements and accompanying conference call, scheduled for August 20, 2024. This event will provide insights into the company's financial performance and corporate updates. The conference call will be accessible to U.S. and international investors, showcasing CollPlant's commitment to communication with stakeholders. The company specializes in regenerative medicine and aesthetic solutions using plant-derived collagen, indicating a focus on innovation in healthcare.
Read more →CLGNCollPlant Biotechnologies Unveils Inaugural ESG and Sustainability Report
CollPlant Biotechnologies has released its first Environmental, Social, and Corporate Governance (ESG) and Sustainability Report for 2023, detailing its initiatives in sustainability and ethical production. The report emphasizes the company's commitment to enhancing plant-based production and reducing emissions through its innovative technologies. CEO Yehiel Tal highlighted the strategic pillars driving CollPlant's sustainability goals, while the report also outlines potential risks associated with fulfilling future objectives, including the need for additional capital and challenges in clinical trials. Overall, this report lays the groundwork for transparent communication regarding the company's sustainability journey.
Read more →CLGNCollPlant Successfully Bio-Prints 200cc Commercial-Size Regenerative Breast Implants and Reports Additional Positive Pre-Clinical Data
CollPlant Biotechnologies has successfully bio-printed 200cc regenerative breast implants using its proprietary rhCollagen bioinks, marking a significant achievement in tissue engineering. The company has reported positive interim pre-clinical data showing effective tissue growth and safety, with further large-animal studies planned for the near future. These developments position CollPlant as a potential leader in regenerative medicine, aiming to offer safer alternatives to conventional synthetic implants. The company's next steps include additional studies set to provide further validation of their technology by early 2025.
Read more →CLGNCollPlant Biotechnologies Announces First Quarter Financial Results For 2024 and Provides Corporate Update
CollPlant Biotechnologies announced its first-quarter financial results for 2024, revealing a significant decrease in revenues to $98,000 compared to $433,000 in Q1 2023. The company continues to develop innovative 3D-bioprinted breast implants aimed at regenerative medicine, with positive results from initial studies. Despite the promising product development, CollPlant reported an increased net loss of $4.2 million, raising concerns about financial stability. Cash reserves remain robust at $23.2 million, allowing continued investment in their technology and ESG initiatives.
Read more →CLGNCOLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
CollPlant Biotechnologies announced that it will report its financial results for the first quarter of 2024 on May 29, 2024. Following the results, a conference call will take place at 10:00 a.m. EDT to discuss the financial outcomes and provide corporate updates. Investors can participate via dial-in or a live webcast, which will also be available for replay afterwards. CollPlant focuses on regenerative and aesthetic medicine using its proprietary plant-based genetic engineering technology.
Read more →CLGNCOLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CollPlant Biotechnologies has reported its financial results for the full year ended December 31, 2023, highlighting significant advancements in its key programs, particularly in collaboration with AbbVie on a dermal filler candidate. The company achieved a major milestone that led to a $10 million payment from AbbVie and initiated a large-animal study for their regenerative breast implants aimed at commercial size, with topline data expected later this year. CollPlant's revenue increased dramatically to $11 million, reflecting the success of its collaboration and product sales. Additionally, the company is prioritizing its resources towards aesthetics and regenerative medicine markets, placing on hold its gut-on-a-chip program for ulcerative colitis treatment.
Read more →CLGNCOLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
CollPlant Biotechnologies, a company specializing in regenerative and aesthetic medicine, has announced that it will report its financial results for the full year of 2023 on April 4, 2024. The company will host a conference call to discuss these results and provide corporate updates at 10:00 a.m. U.S. EDT. With its proprietary plant-based collagen technology and a partnership with Allergan for dermal fillers, CollPlant aims to make significant contributions in various medical fields.
Read more →CLGNCollPlant Issues Letter to Shareholders Rehovot, Israel
CollPlant Biotechnologies issued an optimistic letter to shareholders detailing accomplishments in 2023. The company highlighted advancements in its collaboration with AbbVie, focusing on dermal and soft tissue fillers, as well as progress in regenerative breast implants aimed at addressing significant market needs. CollPlant also announced ongoing efforts in personalized medicine with its gut-on-a-chip program. The letter outlines a commitment to innovation and leadership in regenerative and aesthetic medicine.
Read more →CLGNCollPlant's CEO to Present at the Octane Aesthetic Tech Forum Conference, in Newport Beach, California CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its ...
CollPlant Biotechnologies (Nasdaq: CLGN) announced that its CEO, Yehiel Tal, will present at the Octane Aesthetic Tech Forum on January 25-26, 2024. The presentation will focus on the company's innovative 3D bioprinted regenerative breast implants, which utilize proprietary recombinant human collagen. This conference is significant for industry professionals and investors, highlighting new opportunities in the aesthetics technology space. Despite the promising developments, CollPlant faces challenges including financial losses and regulatory hurdles for its products.
Read more →CLGN▼ -5.3%on this news
CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants
CollPlant Biotechnologies has initiated a preclinical trial for its innovative 3D-bioprinted, regenerative breast implants, expected to conclude by mid-2024. These implants aim to regenerate breast tissue while offering safety advantages over traditional options, addressing significant market demand and safety issues. The company anticipates utilizing findings from this trial for further design optimization and potential FDA discussions. Previous studies indicated promising results in tissue regeneration without adverse effects, marking significant progress in their technology.
Read more →CLGN▼ -6.6%on this news
CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023
CollPlant Biotechnologies reported its third quarter financial results for 2023, highlighting a $10 million milestone payment received from AbbVie and a strong cash position with $29 million available. The company is advancing its programs, including plans to initiate a large-animal study for regenerative breast implants and received a U.S. patent for its photocurable dermal filler. Despite a reported operating loss, the increase in revenues from the previous year indicates progress toward achieving important milestones in their collaborations.
Read more →CLGNCOLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
CollPlant Biotechnologies has announced the date for its third quarter financial results, scheduled for November 29, 2023. The company will host a conference call to discuss the results and provide corporate updates at 10:00 a.m. EDT. This initiative reflects CollPlant's effort to maintain transparency and inform investors about its developments in regenerative medicine, particularly through its rhCollagen technology. The conference call will be accessible to U.S. and international investors, enhancing communication with stakeholders.
Read more →CLGN▲ +24.1%on this news
CollPlant Biotechnologies Announces Patent Granted in U.S. for Photocurable Dermal Filler
CollPlant Biotechnologies has announced the grant of a U.S. patent for its photocurable dermal filler product, aimed at the aesthetics market. The patent, numbered 11,801,329, pertains to a method of filling tissue space under the epidermis through a polymerizable filler solution. This development is part of CollPlant's strategy to leverage its recombinant human collagen technology and expand into high-value markets. The granted patent is expected to bolster the company's market position for many years, expiring in 2039.
Read more →CLGNCollPlant Biotechnologies Joins the United Nations Global Compact, The World
CollPlant Biotechnologies has announced its membership in the UN Global Compact, which emphasizes corporate sustainability and responsible governance. This participation reflects the company's commitment to developing sustainable alternatives in the fields of regenerative and aesthetic medicine. CEO Yehiel Tal expressed pride in joining this global initiative, which aligns with CollPlant's mission to advance environmentally and socially conscious practices within their industry. Additionally, CollPlant's technology focuses on producing non-animal-derived collagen for tissue regeneration and organ manufacturing.
Read more →CLGNCollPlant to Present at the H.C. Wainwright Annual Growth Conference
CollPlant Biotechnologies (NASDAQ: CLGN) announced its participation in the H.C. Wainwright Annual Growth Conference from September 11-13, 2023. The company, known for its innovative rhCollagen technology in regenerative and aesthetic medicine, aims to showcase its advancements in tissue regeneration and organ manufacturing. Deputy CEO Eran Rotem is scheduled to present on September 12th. However, the company faces significant challenges, including a history of financial losses and uncertainties related to product development and regulatory approval.
Read more →CLGNCollPlant Biotechnologies Ltd. 4 Oppenheimer St, Weizmann Science Park Rehovot 7670104, Israel NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To be held on Tuesday
CollPlant Biotechnologies Ltd. is holding an extraordinary general meeting of shareholders on October 10, 2023, to discuss the repricing of certain options for the company's directors and CEO. The meeting will take place at the Goldfarb Gross Seligman & Co. offices in Tel-Aviv, Israel. Shareholders who plan to attend or vote must ensure their shares are represented by submitting proxies by the designated deadline.
Read more →CLGN▲ +6.9%on this news
CollPlant Biotechnologies Announces Second Quarter Financial Results For 2023 with Revenues of $10.2 Million
CollPlant Biotechnologies reported a successful second quarter for 2023, with revenues of $10.2 million, up significantly from the prior year. The company received a $10 million milestone payment from AbbVie for its dermal filler product as part of a strategic collaboration. Additionally, CollPlant is set to launch a large-animal study for its regenerative breast implants by the end of the year and has partnered with Stratasys to develop bioprinting solutions. The company's cash position is strong, bolstered by these developments, allowing for continued investment in innovative technologies.
Read more →CLGNCOLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 SECOND QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
CollPlant Biotechnologies, a regenerative medicine company, has scheduled its second quarter financial results release for August 24, 2023. The company will conduct a conference call to discuss these results and provide corporate updates. This event highlights CollPlant's ongoing efforts to engage with investors and address its innovative developments in tissue regeneration and organ manufacturing technologies.
Read more →CLGNCollPlant Achieves Milestone and To Receive $10 Million From AbbVie in Accordance with its Regenerative Dermal Filler Product Collaboration Agreement
CollPlant Biotechnologies has announced the achievement of a significant milestone in collaboration with AbbVie for the development of a regenerative dermal filler product. As a result, CollPlant will receive a $10 million payment from AbbVie. This milestone marks progress in their agreement to create innovative products using CollPlant's recombinant human collagen technology. The partnership aims to cater to a lucrative market in medical aesthetics, with promising growth estimates.
Read more →CLGN▲ +5.7%on this news
CollPlant Biotechnologies Announces First Quarter Financial Results For 2023 and Provides Corporate Update
CollPlant Biotechnologies reported a positive sales trajectory for its rhCollagen-based products in its Q1 2023 financial results. The company has advanced its collaboration with AbbVie for dermal fillers and secured a partnership with Stratasys for 3D bioprinting applications. Additionally, CollPlant is preparing for a second large-animal study for its regenerative breast implant program, following a successful initial study. Financially, the company reported a GAAP net loss of $3.7 million, which is slightly improved compared to the previous year.
Read more →CLGNCOLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
CollPlant Biotechnologies has announced the date for its 2023 first quarter financial results, set to be released on May 24, 2023. Following the results, the company will host a conference call and webcast to discuss these outcomes and provide corporate updates. CollPlant specializes in regenerative medicine, focusing on 3D bioprinting technologies, and has partnerships with companies such as Allergan for product development and commercialization.
Read more →CLGNAPRIL 202 3 NASDAQ: CLGN Company Overview Our Mission Developing and delivering collagen technology and regenerative medicine products to improve and prolong lives 2 Certain statements in this presentation constitute "fo
Collagen Therapeutics, Inc. (CLGN) is focused on developing collagen technology and regenerative medicine aimed at improving lives. The company utilizes a proprietary plant-based technology platform to produce human collagen at scale, enhancing safety and functionality compared to animal-derived alternatives. As of April 2023, CLGN reported significant financial backing and a diverse product pipeline, supported by a strategic partnership with AbbVie. However, the company faces challenges, including prior financial losses and regulatory uncertainties that could impact future growth.
Read more →CLGN▲ +5.3%on this news
Stratasys and CollPlant Unite Technologies to Transform Healthcare with Industrial-Scale Bioprinting of Tissues and Organs Joint development and commercialization agreement will initially focus on developmen
Stratasys and CollPlant have entered a joint development and commercialization agreement aimed at creating industrial-scale bioprinting solutions for human tissues and organs. The partnership focuses on the development of regenerative breast implants using CollPlant's rhCollagen-based bioinks and Stratasys' advanced P3 bioprinter technology. This initiative not only addresses a significant market opportunity valued at $2.6 billion but also seeks to transform existing breast augmentation procedures by offering alternatives to synthetic silicone implants. Both companies will cross-promote their bioprinting products to enhance market reach and collaboration.
Read more →CLGN▼ -9.9%on this news
Collplant Biotechnologies Announces Full-Year Financial Results For 2022 and Provides Corporate Update
CollPlant Biotechnologies reported its financial results for the full year 2022, highlighting advancements in its strategic collaboration with AbbVie and progress in its regenerative medicine programs. The company has successfully completed preclinical studies for its 3D bioprinted regenerative breast implants and its novel dermal filler, both offering innovative alternatives in their respective markets. Despite a revenue drop compared to the previous year, CollPlant's investment in research and partnerships positions it favorably within regenerative medicine. The company anticipates ongoing developments and milestone achievements as it works to commercialize its products.
Read more →CLGN▲ +7.9%on this news
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2022 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
CollPlant Biotechnologies has announced that it will report its financial results for the year ended December 31, 2022, on March 29, 2023. Following the financial report, the company will host a conference call and webcast to update investors on its performance and other corporate developments. CollPlant specializes in regenerative and aesthetic medicine, particularly through the use of its recombinant human collagen technology in tissue repair and organ manufacturing. The company has previously partnered with Allergan to develop dermal fillers, highlighting its potential in the market.
Read more →CLGN▲ +9.7%on this news
CollPlant Announces Successful Pre-Clinical Results in 3D Bioprinted Regenerative Breast Implants Porcine Study and Full Achievement of Objectives
CollPlant has announced successful pre-clinical results from a large animal study of its 3D bioprinted regenerative breast implants. The study demonstrated promising stages of tissue regeneration and confirmed the safety and efficacy of the implants, with no adverse reactions reported. This advancement supports the potential of rhCollagen-based implants as a safer, more natural alternative for breast reconstruction and augmentation, particularly benefiting patients post-mastectomy. The company plans to advance to a follow-up study using larger implants and later intends to move into human clinical trials.
Read more →CLGNCollPlant Enriches Portfolio of rhCollagen-Based Bioinks with Launch of Collink.3DTM 50L in Powder Form
CollPlant has announced the launch of Collink.3D™ 50L, a recombinant human collagen-based bioink available in powder form designed for 3D bioprinting applications. This new product aims to provide enhanced flexibility in handling, shipping, and storage, catering to the needs of biopharma and academic sectors. The bioink supports a range of applications including drug discovery and the development of transplantable tissues. The launch adds to CollPlant's portfolio, showcasing the company's commitment to offering innovative, animal-free solutions.
Read more →CLGNCollPlant Biotechnologies Provides Business Updates and Third Quarter 2022 Financial Results
Partnership with AbbVie to co-develop rhCollagen-based dermal and soft tissue fillers continues to advance according to plan Co-developing 3D bioprinted human intestine model ("Gut-on-a-Chip") for drug discovery and personalized treatment of ulcerative colitis with Tel-Aviv Univ
Read more →CLGNCollPlant Overview November 2022 Safe harbor statement Certain statements in this presentation constitute "forward - looking statements" within the meaning of Section 27 A of the Securities Act and Section 21 E of the Se
CollPlant Overview November 2022 Safe harbor statement Certain statements in this presentation constitute "forward - looking statements" within the meaning of Section 27 A of the Securities Act and Section 21 E of the Securities Exchange Act and are usually identified by the use
Read more →CLGNCollPlant, Tel Aviv University and Sheba Medical Center Join Forces to Co-Develop rhCollagen-Based 3D Bioprinted Human Intestine Model for Drug Discovery and Personalized Treatment of Ulcerative Colitis
Agreement to accelerate development of a 'Gut-on-a-Chip' tissue model to improve therapeutic choice and outcome of ulcerative colitis patients CollPlant to fund development and receive exclusive license to manufacture and commercialize human intestine tissue model Intestine mod
Read more →CLGN▼ -5.8%on this news
CollPlant Expands rhCollagen-Based Bioink Platform with Launch of Collink.3D™ 90
Collink.3D™ 90 offers additional functionality to address wide range of 3D bioprinting applications, including soft and hard tissues Collink.3D™ 90 demonstrates faster human cell migration into gel matrices compared with a commercial hydrogel widely used for 2D and 3D cell cultu
Read more →CLGNCollPlant to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 17
REHOVOT, Israel, Nov. 3, 2022 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative human-collagen based technologies and products for tissue regeneration and organ manufacturing, today announced that Eran R
Read more →CLGNCollPlant to present at the Dawson James Small Cap Growth Conference on October 12
REHOVOT, Israel, Oct. 3, 2022 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that the Company's Deputy CEO &
Read more →CLGNCollPlant to Present at the International Conference on Biofabrication 2022 in Tuscany, Italy
REHOVOT, Israel, Sept. 19, 2022 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced the Company will make a p
Read more →CLGNCollPlant Biotechnologies to Participate in September Investor Conferences
REHOVOT, Israel, Sept. 6, 2022 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced that Deputy
Read more →CLGNCollPlant Overview August 2022 Safe harbor statement Certain statements in this presentation constitute "forward - looking statements" within the meaning of Section 27 A of the Securities Act and Section 21 E of the Secu
CollPlant Overview August 2022 Safe harbor statement Certain statements in this presentation constitute "forward - looking statements" within the meaning of Section 27 A of the Securities Act and Section 21 E of the Securities Exchange Act and are usually identified by the use o
Read more →CLGNCollPlant Biotechnologies Provides Business Updates and Second Quarter 2022 Financial Results
Co-development of rhCollagen-based dermal and soft tissue fillers with AbbVie is progressing Company's 3D bioprinted regenerative breast implant program remains on track to conclude large animal study in Q4 Development of aseptic process for the production of sterile rhCollagen
Read more →CLGNCollPlant to Present and Exhibit at TERMIS Annual Conference in Toronto, Canada
At the Tissue Engineering and Regenerative Medicine International Society conference, CollPlant will deliver a presentation 'rhCollagen - The Ideal Building Block For 3D Printed and Injectable Scaffolds for Regenerative Medicine' and a poster 'Recombinant Human Collagen-Based Bio
Read more →CLGN▲ +10.5%on this newsshared move
CollPlant Advances its 3D Bioprinted Regenerative Breast Implants into Porcine Study
rhCollagen-based regenerative breast implants address $2.8 billion global breast implant market with revolutionary and potentially safer new product Regenerative breast implants for aesthetic and reconstructive procedures including postmastectomy for cancer patients The study i
Read more →CLGNCollPlant Biotechnologies Provides Business Updates and First Quarter 2022 Financial Results
Co-development of rhCollagen-based dermal and soft tissue filler products with AbbVie is advancing according to plan Launch of large animal study for Company's 3D bioprinted regenerative breast implant program is on track for Q2 2022 Initiate development of a 3D bioprinted tiss
Read more →CLGNCollPlant CEO Yehiel Tal to Moderate ISBF
REHOVOT, Israel, April 25, 2022 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that CEO Yehiel Tal will moderate the Internat
Read more →CLGNCollPlant Overview April 2022 Safe harbor statement Certain statements in this presentation constitute "forward - looking statements" within the meaning of Section 27 A of the Securities Act and Section 21 E of the Secur
CollPlant Overview April 2022 Safe harbor statement Certain statements in this presentation constitute "forward - looking statements" within the meaning of Section 27 A of the Securities Act and Section 21 E of the Securities Exchange Act and are usually identified by the use of
Read more →CLGNCollPlant To Present at the Aesthetics Innovation Summit 2022
REHOVOT, Israel, April 13, 2022 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that Dr. Jasmine Seror, CollPlant's Head of Ae
Read more →CLGN▼ -7.2%on this news· ran to -18% by day 3
CollPlant Biotechnologies Ltd. 4 Oppenheimer St, Weizmann Science Park Rehovot 7670104, Israel NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To be held on Monday
Biotechnologies Ltd. Oppenheimer St, Weizmann Science Park OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS be held on Monday, May 2, 2022 annual and extraordinary general meeting of shareholders of CollPlant Biotechnologies Ltd. (the "Company") will be held at th
Read more →CLGN▲ +15.1%on this newsshared move
CollPlant Biotechnologies Provides Business Updates and Fiscal Year 2021 Financial Results
REHOVOT, Israel, March 24, 2022 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced business updates and financial
Read more →CLGN▲ +15.1%on this news
CELLINK and CollPlant Enter a Collaboration Agreement to Explore Future Large-Scale Production of CollPlant's Regenerative Breast Implants using CELLINK's Bioprinting technologies CollPlant and CELLINK will explore the u
and CollPlant Enter a Collaboration Agreement to Explore Future Large-Scale Production of CollPlant's Regenerative Breast Implants using CELLINK's Bioprinting technologies CollPlant and CELLINK will explore the use of CELLINK's next-generation high throughput extrusion bioprin
Read more →CLGN▼ -8.3%on this news· ran to -22% by day 3
Dea r Sha r e holder s, 2021 has been a pivotal and productive year for CollPlant which resulted in several significant achievements. With our unique and pioneering technology, resilient workforce and strong financial po
1 Dea r Sha r e holder s, 2021 has been a pivotal and productive year for CollPlant which resulted in several significant achievements. With our unique and pioneering technology, resilient workforce and strong financial position, we have made meaningful progress in our business c
Read more →CLGNCollPlant Announces Publication Highlighting its rhCollagen-based Photocurable Dermal Filler in the Plastic and Reconstructive Surgery Journal
Preclinical modeling demonstrates potential for filler to enhance cell proliferation and new tissue regeneration for aesthetic medicine applications REHOVOT, Israel, Dec. 2, 2021 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine comp
Read more →CLGN▼ -8.4%on this news
CollPlant Biotechnologies Provides Business Updates and Third Quarter 2021 Financial Results
REHOVOT, Israel, Nov. 18, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced business updates and financial r
Read more →CLGNCollPlant Announces Commercial Launch of BioInk Platform with Collink.3D™ for Use in 3D Bioprinting of Human Tissues, Scaffolds and Organs
REHOVOT, Israel, Nov. 15, 2021 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced the launch of Collink.3D, a rec
Read more →CLGNCollPlant to Present at Dawson James Small Cap Growth Conference on October 21st
REHOVOT, Israel, Oct. 14, 2021 /PRNewswire/ - CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that the Company's Deputy CEO &
Read more →CLGNCollPlant's rhCollagen BioInk Used by Technion Researchers to Develop 3D Bioprinted Vascularized Tissue Constructs CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue...
REHOVOT, Israel, Oct. 11, 2021 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that its recombinant human coll
Read more →CLGNCollPlant to Present at Fall Harvest - Best Ideas from the Buy-Side on October 5, 2021
REHOVOT, Israel, Sept. 30, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, has been invited to present at the Fall Harves
Read more →CLGNCollPlant CEO Yehiel Tal to Discuss Emerging Uses of rhCollagen in Aesthetic and Regenerative Medicine at NANO.IL.2021 Conference
REHOVOT, Israel, Sept. 27, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that Mr. Yehiel Tal, the Company's CEO, will p
Read more →CLGNCollPlant Overview H.C. Wainwright 23 rd Annual Global Investment Conference Se p t ember 2021 Safe harbor statement Certain statements in this presentation constitute "forward - looking statements" within the meaning of
CollPlant Overview H.C. Wainwright 23 rd Annual Global Investment Conference Se p t ember 2021 Safe harbor statement Certain statements in this presentation constitute "forward - looking statements" within the meaning of Section 27 A of the Securities Act and Section 21 E of the
Read more →CLGNCollPlant CEO Yehiel Tal elected to the Board of Directors of the International Society for Biofabrication (ISBF)
REHOVOT, Israel, Sept. 9, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that Mr. Yehiel Tal, Chief Executive Officer of
Read more →CLGNCollPlant To Present at the H.C. Wainwright Annual Global Investment Conference in September
REHOVOT, Israel, Sept. 7, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that Mr. Yehiel Tal, Chief Executive Officer of
Read more →CLGNCollPlant Biotechnologies Provides Business Updates and Second Quarter 2021 Financial Results
REHOVOT, Israel, Aug. 19, 2021 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced financial results for the second quarter ended J
Read more →CLGNCollPlant Appoints Medical Aesthetics Veteran Alisa Lask to Board of Directors
REHOVOT, Israel, Aug. 19, 2021 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, announced the appointment of Alisa Lask to its Board of Director
Read more →CLGNCollPlant Biotechnologies to Present on the Use of Collagen BioInk as a Platform for 3D Bioprinting of Tissues and Organs at the Biomaterials For 3D Printing Webinar
REHOVOT, Israel, Aug. 16, 2021 /PRNewswire/ - CollPlant (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that Dr. Nadav Orr, Vice President of R&D, will p
Read more →CLGN3D Systems Corporation CollPlant 333 Three D Systems Circle 4 Oppenheimer Street Rock Hill, SC 29730 Rehovot www.3dsystems.com 7670104 Israel NYSE:DDD www.collplant.com NASDAQ :CLGN Investor Contact: investo
3D Systems Corporation CollPlant 333 Three D Systems Circle 4 Oppenheimer Street Rock Hill, SC 29730 Rehovot www.3dsystems.com 7670104 Israel NYSE:DDD www.collplant.com NASDAQ :CLGN Investor Contact: investor.relations@3dsystems.com Investor & Media Contact: Eran Rotem, Deputy C
Read more →CLGNCollPlant Announces Effectiveness of Uplisting to the Nasdaq Global Market®; Ordinary Shares Replace ADSs
REHOVOT, Israel, June 4, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, announced today the uplisting of its ordinary shares to the Nasdaq Global Select Market® effective at the open of market today, Friday, June 4, 2021. CollPlant'
Read more →CLGNCollPlant Biotechnologies Reports First Quarter 2021 Financial Results with Record Revenues of $14.5 Million
REHOVOT, Israel, May 27, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, today announced financial results for the first quarter ended March 31, 2021 and provided an update on the Company's business developments. Dermal filler treatm
Read more →CLGNCollPlant Announces Uplisting to the Nasdaq Global Market® and Transition to Trading of Ordinary Shares Instead of ADSs
REHOVOT, Israel, May 25, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, announced that its ordinary shares have been approved for trading on the Nasdaq Global Market® under the Company's current ticker symbol "CLGN" and will begin tr
Read more →CLGNCollPlant Appoints Additive Manufacturing Executive, Hugh Evans to Its Board of Directors
REHOVOT, Israel, March 29, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced the appointment of Hugh Evans to its Board of Directors, increasing the board to six independent members. U.S.-based Mr. Evans brings extensi
Read more →CLGNCollPlant Biotechnologies Reports Year End Financial Results for Fiscal Year 2020
REHOVOT, Israel, March 26, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, today announced financial results for the full year ended December 31, 2020 and provided an update on the Company's business developments. Certain metrics, inc
Read more →CLGNCollPlant To Present at the H.C. Wainwright Global Life Sciences Conference
REHOVOT, Israel, March 4, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced that Mr. Yehiel Tal, Chief Executive Officer of CollPlant, will provide an overview of the company at the H.C. Wainwright Global Life Sciences
Read more →CLGNTermination of Licensing Agreement for Bioprinting of Scaffolds for Lung Transplants
REHOVOT, Israel, Feb. 25, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) a regenerative and aesthetics medicine company, today announced that on February 24, 2021 it received a notice from Lung Biotechnology, a United Therapeutics subsidiary, informing the Company
Read more →CLGNCollPlant Announces Closing of $35.0 Million Registered Direct Offering of American Depositary Shares
CollPlant Biotechnologies has successfully closed a registered direct offering, raising $35 million through the sale of 2 million American Depositary Shares at $17.50 each. The proceeds will be utilized for general corporate purposes, including the development of regenerative and aesthetic medicine products. The offering was facilitated by H.C. Wainwright & Co., and the ADSs were sold under an effective registration statement with the SEC.
Read more →CLGNCollPlant Issues Letter to Shareholders Expansion of collaboration with United Therapeutics to cover a second lifesaving organ, human kidneys, in addition to lungs Development and commercialization agreement with Allerga
Issues Letter to Shareholders 3D bioprinted trachea using CollPlant's BioInk, courtesy of United Therapeutics and 3D systems REHOVOT, Israel, Feb. 18, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) today announced the following letter from its Chief Executive O
Read more →CLGNCollPlant Announces $35.0 Million Registered Direct Offering of American Depositary Shares
CollPlant Biotechnologies has announced a registered direct offering of 2,000,000 American Depositary Shares (ADSs) at $17.50 each, aiming to raise $35 million. The funds will be utilized for general corporate purposes, including the development of regenerative and aesthetic medicine products. The offering is expected to close around February 17, 2021, pending customary conditions.
Read more →CLGNCollPlant Announces $35.0
CollPlant Announces $35.0 Million Registered Direct Offering of American Depositary Shares REHOVOT, Israel, Feb. 11, 2021 (GLOBE NEWSWIRE) -- CollPlant Biotechnologies (NASDAQ:CLGN), today announced that it has entered into definitive agreements with several healthcare-focuse
Read more →CLGNCollPlant Announces Development and Global Commercialization Agreement with Allergan Aesthetics, an AbbVie company, for rhCollagen in Dermal and Soft Tissue Filler Products
REHOVOT, Israel, Feb. 8, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) today announced it has entered into a worldwide exclusive development and commercialization agreement for dermal and soft tissue filler products with Allergan Aesthetics, an AbbVie company. De
Read more →CLGNCollPlant to Supply rhCollagen to STEMCELL Technologies for Use in a Broad Range of Cell Culture Applications
REHOVOT, Israel and VANCOUVER, BC, Dec. 10, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company, and STEMCELL Technologies, Canada's largest privately owned biotechnology company, which develops cell culture media, cell separation systems, instruments,
Read more →CLGNCollPlant Biotechnologies Reports Third Quarter (Q3) 2020 Financial Results and Provides Business Update
REHOVOT, Israel, Dec. 1, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced financial results for the third quarter ended September 30, 2020 and provided an update on the Company's business developments. Certain metrics,
Read more →CLGNCollPlant Announces Early Development Program of Antiviral Agent for Potential Treatment of COVID-19 Patients
REHOVOT, Israel, Nov. 10, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) a regenerative medicine company, today announced its development program of an antiviral agent for potential treatment of COVID-19 patients. In-vitro early results of CollPlant's formulations showed significa
Read more →CLGNCollPlant Receives Substantial First Order for its Vergenix™ Flowable Gel Product in Ukraine
REHOVOT, Israel, Oct. 26, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) a regenerative and aesthetic medicine company, today announced that it has received a substantial first order totaling hundreds of thousands of U.S. dollars for its Vergenix™ Flowable Gel (FG) product in Ukra
Read more →CLGNCollPlant and United Therapeutics Announce Exercise of Option that will Expand their Collaboration to Include 3D Bioprinting of Human Kidneys for Transplant Expanded collaboration combines CollPlant's proprietary BioInk
CollPlant and United Therapeutics Announce Exercise of Option that will Expand their Collaboration to Include 3D Bioprinting of Human Kidneys for Transplant REHOVOT, Israel and SILVER SPRING, Maryland, September 21, 2020 -- CollPlant Biotechnologies (NASDAQ: CLGN) and United T
Read more →CLGNCollPlant Biotechnologies Presents on the Use of Novel, Plant-Derived, Recombinant Human Collagen for Anti-Aging Therapies at the Science of Aging Virtual Symposium 2020
REHOVOT, Israel, Sept. 16, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) a regenerative and aesthetic medicine company, today announced that Dr. Nadav Orr, Vice President of R&D, presented a corporate overview on the dynamics of cellular aging during Session 3 of the Science of A
Read more →CLGNCollPlant Biotechnologies Signs Distribution Agreement for its Vergenix Flowable Gel Product in the Commonwealth of Independent States (CIS)
REHOVOT, Israel, Sept. 14, 2020 /PRNewswire/ -- CollPlant has already received first order amounting to hundreds of thousands of U.S. dollars Product distribution in six CIS countries expected to increase clinical use in new patient populations Recent peer-reviewed publication
Read more →CLGNCollPlant Biotechnologies Ltd. 4 Oppenheimer St, Weizmann Science Park Rehovot 7670104, Israel NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To be held on
CollPlant Biotechnologies Ltd. 4 Oppenheimer St, Weizmann Science Park Rehovot 7670104, Israel NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To be held on October 13, 2020 The annual and extraordinary general meeting of shareholders of CollPlant Biotec
Read more →CLGNCollPlant Biotechnologies to Present at Science of Aging Virtual Symposium 2020 During Healthy Aging Month
CollPlant’s photocurable regenerative filler[1] combines the advantages of collagen and hyaluronic acid for skin regeneration REHOVOT, Israel, Aug. 31, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) a regenerative and aesthetic medicine company, today announced that Dr. Nadav Orr
Read more →CLGNCollPlant Biotechnologies Reports Second Quarter (Q2) 2020 Financial Results
REHOVOT, Israel, Aug. 28, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced financial results for the second quarter ended June 30, 2020 and provided an update on the Company's business developments. Certain metrics, in
Read more →CLGNCollPlant Biotechnologies Reports First Quarter (Q1) 2020 Financial Results
REHOVOT, Israel, May 27, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced financial results for the first quarter ended March 31, 2020 and provided an update on the Company's business developments. Certain metrics, inc
Read more →CLGNCollplant to Host Webinar Highlighting its Plant-based, Human Recombinant Collagen (rhCollagen) Platform for the Future of Aesthetic and Regenerative Medicine
REHOVOT, Israel, May 5, 2020 /PRNewswire/ -- CollPlant (NASDAQ:CLGN) , a regenerative and aesthetics medicine company, today announced that it will be hosting a webinar on Tuesday, May 12, 2020 at 11 am EDT/6 pm IDT that will feature its Co-Founder and Chief Scientist, Professor
Read more →CLGNCollPlant Biotechnologies Ltd. 4 Oppenheimer St, Weizmann Science Park Rehovot 7670104, Israel NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To be held on
CollPlant Biotechnologies Ltd. 4 Oppenheimer St, Weizmann Science Park Rehovot 7670104, Israel NOTICE OF EXTRAORDINARY GENERAL MEETING To be held on May 14, 2020 general meeting of shareholders of CollPlant Biotechnologies Ltd. (the "Company") will be held at the offices of
Read more →CLGNCollPlant Biotechnologies Reports Year End Financial Results for Fiscal Year 2019
REHOVOT, Israel, April 1, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced financial results for the full year ended December 31, 2019 and provided an update on the Company's business developments. Certain metrics, inc
Read more →CLGNCollPlant Biotechnologies Raising $4.45 Million in U.S. Private Placement
REHOVOT, Israel, Feb. 14, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) (the "Company"), a regenerative and aesthetic medicine company, announced it has entered into definitive agreements for up to $4.45 million. The capital raise is by way of a non-brokered private placement wit
Read more →CLGNJ.
Announces Appointment of J. Pomerantz, M.D., F.A.C.P. Chairman of the Board of Directors Israel, February 10, 2020, CollPlant (NASDAQ:CLGN), a regenerative and aesthetic medicine company, today announced the appointment of Roger J. Pomerantz, M.D., F.A.C.P. to its Board of Di
Read more →CLGNCollPlant Announces Appointment of Roger J. Pomerantz, M.D., F.A.C.P. as Chairman of the Board of Directors
REHOVOT, Israel, Feb. 10, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, today announced the appointment of Roger J. Pomerantz, M.D., F.A.C.P. to its Board of Directors as Chairman, effective immediately. Dr. Pomerantz is currently t
Read more →CLGNLaunches New Corporate Website to Showcase Recent Developments in Core Business Segments
Launches New Corporate Website to Showcase Recent Developments in Core Business Segments Rehovot, Israel, February 4, 2020, CollPlant (NASDAQ:CLGN), a regenerative and aesthetic medicine company, today announced the launch of its updated corporate website. The new website has a
Read more →CLGNCollPlant Launches New Corporate Website to Showcase Recent Developments in Core Business Segments
REHOVOT, Israel, Feb. 4, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, today announced the launch of its updated corporate website. The new website has a clean uncluttered design, improved functionality and enhanced rich content foc
Read more →CLGNSystems and CollPlant Biotechnologies Join Forces to Accelerate Breakthroughs in Regenerative Medicine
3D Systems Corporation CollPlant 333 Three D Systems Circle 4 Oppenheimer Street Rock Hill, SC 29730 Rehovot www.3dsystems.com 7670104 Israel NYSE:DDD www.collplant.com NASDAQ :CLGN Investor Contact: Email: investor.relations@3dsystems.com Investor & Media Contact: Eran Rotem,
Read more →CLGN3D Systems and CollPlant Biotechnologies Join Forces to Accelerate Breakthroughs in Regenerative Medicine
ROCK HILL, South Carolina and REHOVOT, Israel, Jan. 13, 2020 /PRNewswire/ -- Today, 3D Systems (NYSE: DDD) and CollPlant Biotechnologies (NASDAQ: CLGN), announced signing a joint development agreement intended to play a pivotal role in advancing and accelerating breakthroughs in
Read more →CLGNCollPlant Partners in the Advanced Regenerative Manufacturing Institute
REHOVOT, Israel, Jan. 6, 2020 /PRNewswire/ -- CollPlant (NASDAQ:CLGN), a regenerative medicine company, today announced it is now part of a new public-private ManufacturingUSA initiative, the Advanced Regenerative Manufacturing Institute (ARMI). Headquartered in Manchester, New H
Read more →CLGNCollPlant Publishes Letter to Shareholders Rehovot
CollPlant Publishes Letter to Shareholders Rehovot, December 19, 2019, CollPlant (NASDAQ:CLGN), a regenerative medicine company, today announced that Yehiel Tal, Chief Executive Officer of CollPlant Biotechnologies, has issued a Letter to Shareholders, the full text of which f
Read more →CLGNCollPlant Publishes Letter to Shareholders
REHOVOT, Israel, Dec. 19, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company, today announced that Yehiel Tal, Chief Executive Officer of CollPlant Biotechnologies, has issued a Letter to Shareholders, the full text of which follows below. Dear Fellow
Read more →CLGNCollPlant Reports Third Quarter 2019 Financial Results and Provides Business Update
REHOVOT, Israel, Nov. 29, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company, today announced financial results for the third quarter ended September 30, 2019 and provided an update on the Company's business developments. Certain metrics, including tho
Read more →CLGNCollPlant CEO Yehiel Tal Appointed to Serve on International Society for Biofabrication
REHOVOT, Israel, Oct. 22, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company, today announced the Company's Chief Executive Officer Yehiel Tal was recently appointed as a member of the Industry Relations Committee of ISBF (International Society for Bio
Read more →CLGNCollPlant to Present at Dawson James Small Cap Growth Conference on October 29, 2019 in Florida
REHOVOT, Israel, Oct. 16, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company, today announced the Company's Chief Executive Officer Yehiel Tal will present at the Dawson James 5th Annual Small Cap Growth Conference on Tuesday, October 29, 2019 at 1:10
Read more →CLGNCollPlant Reports Second Quarter 2019 Financial Results and Provides Business Update
REHOVOT, Israel, Sept. 26, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company, today announced financial results for the second quarter ended June 30, 2019 and provided an update on the Company's business developments. Certain metrics, including those
Read more →CLGNCollPlant Biotechnologies Closes on $5.5 Million Financing
REHOVOT, Israel, Sept. 9, 2019 /PRNewswire/ -- CollPlant (NASDAQ:CLGN) (the "Company"), a regenerative medicine company, announced it has closed on a total of $5.5 million in convertible loans. A group of U.S. accredited investors with deep experience in the 3D printing industry
Read more →CLGNCollPlant Overview HCW Global Investment Conference September 2019
CollPlant Overview HCW Global Investment Conference September 2019 Safe Harbor Statement Certain statements in this presentation constitute "forward - looking statements" within the meaning of Section 27 A of the Securities Act and Section 21 E of the Securities Exchange Act and
Read more →CLGNCollPlant Biotechnologies to Present at the 21st Annual Rodman & Renshaw Global Investment Conference
REHOVOT, Israel, Sept. 5, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company, today announced that Yehiel Tal, Chief Executive Officer will be presenting at the 21st Annual Global Rodman and Renshaw Investment Conference, sponsored by H. C. Wainwright,
Read more →CLGNBiotechnologies Raising $5.5 Million
Biotechnologies Raising $5.5 Million include CollPlant's largest shareholder and U.S. tech investors Israel, September 3, 2019, CollPlant (NASDAQ:CLGN) (the "Company"), a regenerative medicine company, announced it has entered into definitive agreements for up to $6.5 million
Read more →CLGNCollPlant Biotechnologies Raising $5.5 Million
REHOVOT, Israel, Sept. 3, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) (the "Company"), a regenerative medicine company, announced it has entered into definitive agreements for up to $6.5 million funding in convertible loans. The capital raise is by way of a non-brokered private
Read more →CLGNis Developing 3D-bioprinted Implants
is Developing 3D-bioprinted Implants Regeneration of Breast Tissue August 5, 2019, CollPlant (NASDAQ:CLGN) (the "Company"), a regenerative medicine company, announced today that it is developing 3D bioprinted implants for regeneration of breast tissue and has successfully prod
Read more →CLGNCollPlant is Developing 3D-bioprinted Implants for Regeneration of Breast Tissue
REHOVOT, Israel, Aug. 5, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) (the "Company"), a regenerative medicine company, announced today that it is developing 3D bioprinted implants for regeneration of breast tissue and has successfully produced first prototypes. The implants wil
Read more →CLGNCollPlant Announces Corporate Name Change to CollPlant Biotechnologies to Better Reflect Its Business
REHOVOT, Israel, June 20, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) (the "Company"), a regenerative medicine company, announced today that its corporate name has changed from "CollPlant Holdings Ltd." to "CollPlant Biotechnologies Ltd." effective on the opening of trading on
Read more →CLGNClinical Results from CollPlant's
Clinical Results from CollPlant's Advanced Wound Care Product VergenixFG to be Presented at European Wound Management Association Conference Rehovot, June 4, 2019, CollPlant (NASDAQ:CLGN), a regenerative medicine company, today announced that the results from a clinical study
Read more →CLGNClinical Results From CollPlant
REHOVOT, Israel, June 4, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company, today announced that the results from a clinical study conducted with its VergenixFG advanced wound care product will be presented at the 29th Conference of the European Wound
Read more →CLGNCollPlant Reports First Quarter 2019
CollPlant Reports First Quarter 2019 Financial Results and Provides Business Update Rehovot, May 30, 2019, CollPlant (NASDAQ:CLGN), a regenerative medicine company, today announced financial results for the first quarter ended March 31, 2019 and provided an update on the Com
Read more →CLGNCollPlant Reports First Quarter 2019 Financial Results and Provides Business Update
REHOVOT, Israel, May 30, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company, today announced financial results for the first quarter ended March 31, 2019 and provided an update on the Company's business developments. Certain metrics, including those ex
Read more →CLGNCollPlant Presents Its rhCollagen-based BioInks for 3D Bioprinting of Tissues and Organs at TERMIS Annual Meeting in Rhodes, Greece
REHOVOT, Israel, May 28, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company, today announced that Dr. Nadav Orr, the Company's Vice President for R&D, presented the utilization of CollPlant's recombinant human collagen (rhCollagen) in the field of 3D B
Read more →CLGNPresents its rhCollagen-based BioInks for 3D Bioprinting of Tissues and Organs at TERMIS Annual Meeting in Rhodes, Greece
Presents its rhCollagen-based BioInks for 3D Bioprinting of Tissues and Organs at TERMIS Annual Meeting in Rhodes, Greece May 28, 2019, CollPlant (NASDAQ:CLGN), a regenerative medicine company, today announced that Dr. Nadav Orr, the Company's Vice President for R&D, presented
Read more →CLGNCollPlant Launches New HQ and R&D Center in Israel
REHOVOT, Israel, May 22, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company, has launched a new HQ and R&D center in Israel. CollPlant is developing, manufacturing and commercializing products for tissue repair and organ manufacturing from its proprie
Read more →CLGNCollPlant Holdings Ltd. 4 Oppenheimer St, Weizmann Science Park Rehovot 7670104, Israel NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To be held on
4 Oppenheimer St, Weizmann Science Rehovot 7670104, Israel OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS be held on June 6, 2019 general meeting of shareholders of CollPlant Holdings Ltd. (the "Company") will be held at the offices of Gross, Kleinhendler, Hodak, Halevy, G
Read more →CLGNCollPlant Announces Publication of Study in Science Translational Medicine Showing Composite Matrix Based on rhCollagen, Ceramics and Bone Morphogenic Protein Led to Bone Growth Superior to Standard of Care
REHOVOT, Israel, April 24, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company, today announced the publication of a study titled, "Bone Repair with a Receptor Optimized BMP-2/6/Activin Chimera Delivered In a Novel Ceramic/rhCollagen Matrix is Superior
Read more →CLGNCollPlant to Present at ThinkEquity Conference on May 2, 2019 in New York City
REHOVOT, Israel, April 23, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company, today announced the Company will present at the ThinkEquity Conference on Thursday, May 2, 2019 at 10:00 am ET in the Lotus East room of the Mandarin Oriental Hotel in New Y
Read more →CLGNReports Fourth Quarter and Year End 2018 Financial Results and Provides Business Update
Reports Fourth Quarter and Year End 2018 Financial Results and Provides Business Update April 1, 2019, CollPlant (NASDAQ:CLGN), a regenerative medicine company, today announced financial results for the fourth quarter and year ended December 31, 2018 and provided an update on t
Read more →CLGNCollPlant Reports Fourth Quarter and Year End 2018 Financial Results and Provides Business Update
REHOVOT, Israel, April 1, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company, today announced financial results for the fourth quarter and year ended December 31, 2018 and provided an update on the Company's business developments. Certain metrics, incl
Read more →CLGNCollPlant Renews Distribution Agreement
CollPlant Renews Distribution Agreement for its Soft Tissue Repair Product Vergenix STR with Arthrex a World Leader in Orthopedics Distribution in Europe, Middle East, India and Africa for the treatment of tendinopathy Ness Ziona, Israel, March 18, 2019 -- CollPlant (Nasdaq
Read more →CLGNCollPlant Renews Distribution Agreement for Its Soft Tissue Repair Product Vergenix™STR With Arthrex a World Leader in Orthopedics
NESS ZIONA, Israel, March 18, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company, today announced that it has renewed its exclusive distribution agreement with Arthrex for Vergenix™STR for the treatment of tendinopathy. The original distribution agreem
Read more →CLGNStudy Published in Wounds Journal Shows
Study Published in Wounds Journal Shows Remarkable Wound Closure Performance with CollPlant's VergenixFG in the Treatment of Chronic Wounds with a 94% Median Wound Area Reduction within 4-weeks Ness Ziona, Israel, March 11, 2019 -- CollPlant (Nasdaq: CLGN), a regenerative med
Read more →CLGNStudy Published in Wounds Journal Shows Remarkable Wound Closure Performance With CollPlant
NESS ZIONA , Israel, March 11, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company, today announced results from a clinical study conducted with its VergenixFG wound care product. The results were published in Wounds, a peer-reviewed journal focusing on
Read more →CLGNCollPlant Holdings Ltd. 3 Sapir Street, Weizmann Science Park Ness-Ziona Israel NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To be held on
3 Sapir Street, Weizmann Science Park OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS be held on March 28, 2019 extraordinary general meeting of shareholders of CollPlant Holdings Ltd. (the "Company") will be held at the offices of Gross, Kleinhendler, Hodak, Halevy, Greenbe
Read more →CLGNAnnounces Approval of its rhCollagen Manufacturing Facility by
Announces Approval of its rhCollagen Manufacturing Facility by European Union Notified Body produces proprietary rhCollagen used for BioInks in 3D bioprinting of organs and for dermal fillers Ness Ziona, Israel, February 19, 2019 -- CollPlant (Nasdaq: CLGN), a regenerative me
Read more →CLGNCollPlant Announces Approval of Its rhCollagen Manufacturing Facility by European Union Notified Body
NESS ZIONA, Israel, Feb. 19, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company, today announced its production facility in Rehovot, Israel has received DEKRA (European Union Notified Body) Certification, for the manufacturing and purification of its r
Read more →CLGNCollPlant Announces Appointment of Jonathan M.N. Rigby as Chairman of the Board
NESS ZIONA, Israel, Feb. 4, 2019 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative medicine company, today announced that Jonathan M.N. Rigby has been appointed as Chairman of the Board of Directors effective immediately. Mr. Rigby brings to CollPlant over 28 years of expe
Read more →CLGNAnnounces Appointment of Jonathan M.N.
Announces Appointment of Jonathan M.N. Rigby as Chairman of the Board Ziona, Israel, February 4, 2019 -- CollPlant (Nasdaq: CLGN), a regenerative medicine company, today announced that Jonathan M.N. Rigby has been appointed as Chairman of the Board of Directors effective immedi
Read more →CLGNClinical Trial Published in the Journal
Clinical Trial Published in the Journal of Shoulder and Elbow Surgery Concludes that CollPlant's Vergenix STR Effectively Demonstrates Significant Clinical Improvements in Tennis Elbow - 59% improvement in a key measure in patients with chronic tennis elbow at 6 months after
Read more →CLGNClinical Trial Published in the Journal of Shoulder and Elbow Surgery Concludes That CollPlant
NESS ZIONA, Israel, December 10, 2018 /PRNewswire/ -- 59% improvement in a key measure in patients with chronic tennis elbow at 6 months after treatment Vergenix™STR is currently sold in Europe; CollPlant plans to pursue FDA regulatory approval in U.S. CollPlant (NASDAQ: CLGN)
Read more →CLGNCollPlant Reports Third Quarter 2018 Financial Results and Provides Business Update
NESS ZIONA, Israel, Nov. 29, 2018 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), today announced financial results for the third qu
Read more →CLGNReports Third Quarter 2018 Financial Results and
Reports Third Quarter 2018 Financial Results and Ziona, November 29, 2018, CollPlant (NASDAQ:CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), today announced financia
Read more →CLGNAnnounces Closing of Global Licensing and Commercialization Agreement with United Therapeutics for
Announces Closing of Global Licensing and Commercialization Agreement with United Therapeutics for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplants Combines CollPlant's Proprietary rhCollagen-based BioInk Technology and United Therapeutics' Regenerative Medicine
Read more →CLGNCollPlant Announces Closing of Global Licensing and Commercialization Agreement With United Therapeutics for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplants
NESS ZIONA, Israel, November 12, 2018 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) today announced the closing of a worldwide exclusive license, development and commercialization agreement with United Therapeutics Corporation (NASDAQ: UTHR) for 3D bioprinted lung transplants. Effect
Read more →CLGNCollPlant to Ring Nasdaq Opening Bell on November 8, 2018
NESS ZIONA, Israel, November 7, 2018 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), today announced that management will be ringin
Read more →CLGNCollPlant Holdings Ltd. 3 Sapir Street, Weizmann Science Park Ness-Ziona Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on
CollPlant Holdings Ltd. 3 Sapir Street, Weizmann Science Park NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on December 13, 2018 meeting of Shareholders of CollPlant Holdings Ltd. (the "Company") will be held at the offices of Gross, Kleinhendler, Hodak, Halevy
Read more →CLGNCollplant Shares Will Be Traded From Tuesday October 30 Exclusively on Nasdaq - Last trading day on the Tel Aviv Stock Exchange (TASE) on
Will Be Traded From Tuesday October 30 Exclusively on Nasdaq Ness Ziona, October 28, 2018, CollPlant (NASDAQ:CLGN, TASE:CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen (recombinant human collagen) technology for tissue repair products, t
Read more →CLGNCollPlant Shares Will Be Traded From Tuesday Oct 30 Exclusively on Nasdaq
NESS ZIONA, Israel, Oct. 28, 2018 /PRNewswire/ -- CollPlant (NASDAQ:CLGN, TASE:CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen (recombinant human collagen) technology for tissue repair products, today announced that as from Tuesday, October
Read more →CLGNand United Therapeutics Announce Global Licensing and
and United Therapeutics Announce Global Licensing and Commercialization Agreement for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplants Combines CollPlant's Proprietary rhCollagen-based Bioink Technology and United Therapeutics' Regenerative Medicine and Organ Ma
Read more →CLGNCollPlant Reports Second Quarter 2018 Financial Results and Provides Business Update
NESS ZIONA, Israel, Sept. 21, 2018 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) (TASE: CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), today announced financial results fo
Read more →CLGNCollPlant Holdings to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
NESS ZIONA, Israel, August 28, 2018 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) (TASE: CLGN) a regenerative medicine company utilizing its proprietary plant-based rhCollagen (recombinant human collagen) technology for tissue repair products, today announced that it will be featured
Read more →CLGNDual-Listed CollPlant to Voluntarily Delist From Tel Aviv Stock Exchange
NESS ZIONA, Israel, Aug. 8, 2018 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) (TASE: CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen (recombinant human collagen) technology for tissue repair products, today announced that the Company is volunta
Read more →CLGNCollPlant to Voluntarily Delist from Tel Aviv Stock Exchange
CollPlant to Voluntarily Delist from Tel Aviv Stock Exchange Ziona, August 8, 2018, CollPlant (NASDAQ:CLGN, TASE:CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen (recombinant human collagen) technology for tissue repair products, today ann
Read more →CLGNCollPlant Appoints Dr. Wolfgang Ruttenstorfer to Its Board of Directors
NESS ZIONA, Israel, July 5, 2018 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) (TASE: CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen (recombinant human collagen) technology for tissue repair products, today announced the appointment of Dr. Wolf
Read more →CLGNAppoints Dr.
Appoints Dr. Wolfgang Ruttenstorfer to its Board of Directors Ziona, July 5, 2018, CollPlant (NASDAQ: CLGN, TASE: CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen (recombinant human collagen) technology for tissue repair products, today an
Read more →CLGNReceives Research and Development Project Approval from the Israel Innovation Authority to
Receives Research and Development Project Approval from the Israel Innovation Authority to Advance its Collagen-Based BioInk for 3D Printing of Tissues and Organs Ziona, June 26, 2018, CollPlant (NASDAQ:CLGN, TASE:CLGN), a regenerative medicine company utilizing its proprietar
Read more →CLGNCollPlant Receives Research and Development Project Approval From the Israel Innovation Authority to Advance its Collagen-based BioInk for 3D Printing of Tissues and Organs
NESS ZIONA, Israel, June 26, 2018 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) (TASE: CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen (recombinant human collagen) technology for tissue repair products, today announced that it has received gran
Read more →CLGNCollPlant Appoints Professor Shay Soker from Wake Forest Institute for Regenerative Medicine to its Scientific Advisory Board
NESS ZIONA, Israel, June 19, 2018 /PRNewswire/ -- CollPlant (NASDAQ:CLGN) (TASE:CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen (recombinant human collagen) technology for tissue repair products, today announced the appointment of Shay Soke
Read more →CLGNCollPlant Holdings Ltd. 3 Sapir Street, Weizmann Science Park Ness-Ziona Israel NOTICE TO SHAREHOLDERS, HOLDERS OF SERIES I WARRANTS AND SERIES K WARRANTS
3 Sapir Street, Weizmann Science Park TO SHAREHOLDERS, HOLDERS OF SERIES I WARRANTS AND SERIES K WARRANTS May 3, 2018, CollPlant Holdings Ltd. (the "Company") announced that on June 7, 2018 it will hold at the offices of Gross, Kleinhendler, Hodak, Halevy, Greenberg & Co. law
Read more →CLGNCollPlant Reports First Quarter 2018 Financial Results and Provides Business Update
NESS ZIONA, Israel, May 24, 2018 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) (TASE: CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), today announced financial results for
Read more →CLGNFiles U.S.
Files U.S. Patent Application for Ness Ziona, May 8, 2018, CollPlant (NASDAQ:CLGN , TASE: CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), announced that it has file
Read more →CLGNCollPlant Files U.S. Patent Application for Next Generation Dermal Filler
NESS ZIONA, Israel, May 8, 2018 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) (TASE: CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), announced that it has filed a provisio
Read more →CLGNCollPlant Holdings Ltd. 3 Sapir Street, Weizmann Science Park Ness-Ziona Israel NOTICE OF EXTRAORDINARY GENERAL MEETINGS OF SHAREHOLDERS AND HOLDERS OF SERIES I WARRANTS AND SERIES K WARRANTS To Be Held on
CollPlant Holdings Ltd. 3 Sapir Street, Weizmann Science Park NOTICE OF EXTRAORDINARY GENERAL MEETINGS OF SHAREHOLDERS AND HOLDERS OF SERIES I WARRANTS AND SERIES K WARRANTS To Be Held on June 7, 2018 Notice is hereby given that three separate extraordinary general meeting
Read more →CLGNCollPlant Announces Completion of the Third Closing of Alpha Investment
NESS ZIONA, Israel, May 1, 2018 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) (TASE: CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), today announced that it has completed
Read more →CLGNCollPlant Opens a New rhCollagen Production Facility
NESS ZIONA, Israel, April 23, 2018 /PRNewswire/ -- CollPlant (NASDAQ:CLGN) (TASE:CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products today announced the opening of a new rhCollagen production facility in R
Read more →CLGNPetitions Court to Voluntarily Delist Ordinary Shares from the Tel Aviv Stock Exchange
Petitions Court to Voluntarily Delist Ordinary Shares from the Tel Aviv Stock Exchange Ziona, April 16, 2018, CollPlant (NASDAQ:CLGN, TASE:CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant
Read more →CLGNCollplant Petitions Court to Voluntarily Delist Ordinary Shares From the Tel Aviv Stock Exchange
NESS ZIONA, Israel, April 16, 2018 /PRNewswire/ -- CollPlant (NASDAQ:CLGN) (TASE:CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), announced that it petitioned the Dist
Read more →CLGNCollPlant Appoints Revital Mandil-Levin
CollPlant Appoints Revital Mandil-Levin as Chief Business Development Officer Ness Ziona, April 12, 2018, CollPlant (NASDAQ:CLGN, TASE:CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant hu
Read more →CLGNCollPlant Appoints Revital Mandil-Levin as Chief Business Development Officer
NESS ZIONA, Israel, April 12, 2018 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) (TASE: CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), announced the appointment of Revital
Read more →CLGNCollPlant Reports Fourth Quarter and
CollPlant Reports Fourth Quarter and Year End 2017 Financial Results and Provides Business Update Ness Ziona, March 21, 2018, CollPlant (NASDAQ:CLGN, TASE:CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair prod
Read more →CLGNCollPlant Reports Fourth Quarter and Year End 2017 Financial Results and Provides Business Update
NESS ZIONA, Israel, March 21, 2018 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) (TASE:CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), today announced financial results fo
Read more →CLGNCollPlant Joins ReMDO
NESS ZIONA, Israel, February 21, 2018 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) (TASE: CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), announced that it is part of ReM
Read more →CLGNCollPlant Announces ADS Listing on NASDAQ
NESS ZIONA, Israel, January 31, 2018 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) (TASE: CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), announced that its American Depos
Read more →CLGNCollPlant Announces ADS Listing on NASDAQ Ness Ziona, Israel
CollPlant Announces ADS Listing on NASDAQ Ness Ziona, Israel, January 31, 2018 CollPlant (NASDAQ: CLGN, TASE:CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, rhCollagen ), announced
Read more →CLGNCollPlant Appoints David Tsur as Chairman of the Board
NESS ZIONA , Israel, January 16, 2018 /PRNewswire/ -- CollPlant (TASE: CLPT, OTC: CQPTY), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), announced the appointment of David
Read more →CLGNCollPlant Expands European Sales Network: The Company Has Signed a Distribution Agreement in Greece and Cyprus for Vergenix®FG for Treatment of Acute and Chronic Wounds and Surgical Cuts
NESS ZIONA, Israel, Nov. 28, 2017 /PRNewswire/ -- CollPlant (TASE: CLPT, OTC: CQPTY) - a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), announced that it has signed an agreeme
Read more →CLGNCollPlant Receives Substantial, Repeat Order for Its Biological Ink
NESS ZIONA, Israel, November 28, 2017 /PRNewswire/ -- CollPlant (TASE: CLPT) (OTC: CQPTY), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), announced that it has received an
Read more →CLGNVote of Confidence in CollPlant: Completion of Agreement for Immediate Investment of USD 1.1 Million from Ami Sagi, one of the Company
NESS ZIONA, Israel, Nov. 13, 2017 /PRNewswire/ -- CollPlant (TASE: CLPT, OTC:CQPTY)- a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), announces that it has signed a private re
Read more →CLGNInnovation Authority Gives Vote of Confidence: CollPlant Receives Innovation Authority Approval for USD One Million R&D Program with 40% Funding
NESS ZIONA, Israel, October 30, 2017 /PRNewswire/ -- CollPlant (TASE: CLPT) - a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), announces that it has received the Ministry of
Read more →CLGNCollPlant Signs Definitive Agreement for $5 Million Private Placement with US Investor
NESS ZIONA, Israel, September 11, 2017 /PRNewswire/ -- CollPlant (TASE: CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen (recombinant human Collagen") technology for tissue repair products, announced the signing of a definitive agreement wit
Read more →CLGNCollPlant in Advanced Negotiations for US Private Placement of USD 5.0 million; Agreement Includes Plan for NASDAQ Uplisting
NESS ZIONA, Israel, September 5, 2017 /PRNewswire/ -- CollPlant (TASE: CLPT) - a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), announce that management is in advanced negoti
Read more →CLGNCollPlant Files Patent for 3D Bio-Printing of Organs and Tissues
NESS ZIONA, Israel, June 12, 2017 /PRNewswire/ -- CollPlant (TASE: CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), announced that it has filed a patent application in
Read more →CLGNCollPlant Provides Operational Update for Q1 2017
NESS ZIONA, Israel, May 31, 2017 /PRNewswire/ -- CollPlant (TASE: CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen (recombinant human "rhCollagen") technology for tissue repair products, provided an operational update for the first quarter
Read more →CLGNCollPlant Extends its European Distribution Network With Signing of New Distribution Agreement in Turkey for Vergenix®FG Wound Treatment
NES ZIONA, Israel, May 22, 2017 /PRNewswire/ -- CollPlant (TASE: CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen (recombinant human "rhCollagen") technology for tissue repair products announced that the Company has signed a new, exclusive d
Read more →CLGNCollPlant Establishes a Separate Division to Focus on 3D Bio-Printing of Organs and Tissues
NESS ZIONA, Israel, May 11, 2017 /PRNewswire/ -- CollPlant (TASE: CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), today announced that, following the expansion of its
Read more →CLGNCollPlant Reports Positive Results From Post-Marketing Surveillance of Vergenix®FG
NESS ZIONA, Israel, April 11, 2017 /PRNewswire/ -- CollPlant (TASE: CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), announce positive results from post-marketing surv
Read more →CLGNCollPlant Provides Commercial and Operational Update
NESS ZIONA, Israel, March 30, 2017 /PRNewswire/ -- Progressed to commercial stage with the signing of Vergenix™FG and Vergenix™STR distribution and sales agreements in Europe Progressed development of 3D bioInk, the Company's rhCollagen formulations to be used as biological ink
Read more →CLGNCollPlant Receives CE Mark for Vergenix™STR for Treatment of Tendinopathy
NESS ZIONA, Israel, October 19, 2016 /PRNewswire/ -- CollPlant (TASE: CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen (recombinant human collagen) technology for tissue repair products, today announced that it has achieved a significant mi
Read more →CLGNCollPlant Receives CE Mark for Vergenix™FG Wound Filler
NESS ZIONA, Israel, February 23, 2016 /PRNewswire/ -- CollPlant Ltd. (TASE:CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products, today announced that it has received its CE Mark for Vergenix™FG, a flowable
Read more →CLGNCollPlant to Present Results of its Product for the Treatment in Tendinopathy, at the 4th TERMIS Congress Which Will Take Place in Boston
NESS ZIONA, Israel, September 8, 2015 /PRNewswire/ -- CollPlant (TASE:CLPT), a clinical stage regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products, announced today that Dr. Nadav Orr, the company's Vice President fo
Read more →CLGNCollPlant Executes Non-binding Term Sheet to Develop and Commercialize a Novel Product for Spinal Fusion and Trauma Indications in Collaboration with Leading US Partner
NESS ZIONA, Israel, July 13, 2015 /PRNewswire/ -- CollPlant (TASE:CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products, announced today that it has signed a non-binding term sheet with a leading U.S company
Read more →CLGNAnother Clinical Trial for CollPlant: Trials for Vergenix®STR Have Begun - a Human Collagen-based Product for Tendon Repair
REHOVOT, Israel, January 12, 2015 /PRNewswire/ -- CollPlant (TASE: CLPT), developer and manufacturer of human collagen-based medical products, announces that it has begun human clinical trials with its tendon repair product " Vergenix®STR ", and has recruited and treated the fir
Read more →CLGNCollPlant Launched a Clinical Trial With Vergenix®FG; A Gel Based on a Human Collagen for the Treatment of Chronic Wounds
REHOVOT, Israel, December 1, 2014 /PRNewswire/ -- CollPlant (TASE: CLPT), a developer and manufacturer of human collagen-based medical products announced that it has enrolled and treated the first patient in its Vergenix®FG clinical trial in Israel. The Vergenix®FG gel is an ad
Read more →CLGNCollPlant Names Dr. Nadav Orr Vice President Research and Development
REHOVOT, Israel, September 8, 2014 /PRNewswire/ -- CollPlant (TASE: CLPT), a developer and manufacturer of human collagen-based medical products has announced that Dr. Nadav Orr has been appointed Vice President of Research & Development, effective September 7, 2014. Dr. Nadav
Read more →CLGNCollPlant Holds Intellectual Property Rights in USA - One of the Largest Target Markets for the Company
REHOVOT, Israel, June 23, 2014 /PRNewswire/ -- CollPlant (TASE: CLPT), a developer and manufacturer of human collagen-based medical products announces, announce that the US Patent Office has approved its patent for processing methods for human collagen from plants. This buys Col
Read more →CLGNCollPlant Takes a Step Closer to Commercializing its Vergenix Flowable Gel Product for Treating Wounds: Receives Approval to Carry Out Clinical Trial
REHOVOT, Israel, June 16, 2014 /PRNewswire/ -- CollPlant (TASE: CLPT), developer and manufacturer of human collagen-based medical products announces that it has received approval from the Israeli Ministry of Health to carry out clinical trial with its Flowable Gel, an advanced a
Read more →CLGNCollPlant Takes Significant Steps Towards Sales in Europe
NESS ZIONA, Israel, December 17, 2012 /PRNewswire/ -- CollPlant (TASE:CLPT) designer and manufacturer of medical products based on a recombinant protein sourced from tobacco plants, announced today that it received CE mark approval for European sale and marketing of its Vergenix
Read more →Competitive Position
How CLGN ranks across every disease it competes inCompetitive Position is a premium feature
See how CLGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial